Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Lara C. Pullen, PhD

Lara C. Pullen, PhD, is a medical writer with a PhD in microbiology/immunology from Northwestern University’s Feinberg School of Medicine. As a medical writer she has covered topics as diverse as diabetes, cardiovascular disease, and autism. Her favorite subject, however, is the role of the immune system in health and disease. Dr. Pullen is also the mother of three children, the youngest of whom has Prader-Willi Syndrome (PWS). She is an active member of the PWS community and a thought leader on the importance of the ketogenic diet for this patient population.

Articles by Lara C. Pullen, PhD

Latest Research on Cutaneous Vasculitis Diagnosis, Treatment

Lara C. Pullen, PhD  |  July 14, 2017

CHICAGO—Warren Piette, MD, professor of dermatology at Rush University Medical Center, Chicago, updated rheumatologists on the topic of cutaneous vasculitis at the ACR’s State-of-the-Art Clinical Symposium in April. He began by explaining that the current vasculitis criteria developed by the ACR in 1990 and the Chapel Hill Consensus Conference (CHCC) in 1994 are inadequate to incorporate…

Advancements in Diagnosis, Treatment for Antiphospholipid Syndrome

Lara C. Pullen, PhD  |  July 14, 2017

CHICAGO—Doruk Erkan, MD, MPH, a rheumatologist at the Hospital for Special Surgery and Weill Cornell Medicine in New York City, described recent developments in the field of antiphospholipid syndrome (APS) to the rheumatologists gathered for the ACR’s State-of-the-Art Clinical Symposium in April. He introduced APS as a “field with limited data and lots of controversies,” although,…

Amyloidosis Is Often Underdiagnosed, Undertreated

Lara C. Pullen, PhD  |  July 14, 2017

CHICAGO—Caryn A. Libbey, MD, clinical associate professor of medicine at Boston University School of Medicine, described the evolving in our understanding of amyloid at the ACR’s State-of-the-Art Clinical Symposium in April. Amyloidosis is a rare disease that is often underdiagnosed and undertreated. “Even though this disease has been around for 150 years, I still consider it…

Vitamin D May Improve Outcomes for Patients with Early RA

Lara C. Pullen, PhD  |  July 10, 2017

A recent study examined the differences in T helper cell subtypes and osteoclast precursors between patients with early RA and healthy controls. Researchers found that standard treatment combined with a single dose of cholecalcipherol may better improve the general health of patients…

Genes Connect Parkinson’s Disease to Autoimmune Diseases

Lara C. Pullen, PhD  |  July 3, 2017

A study has identified several common genetic pathways between Parkinson’s disease and autoimmune diseases. Specifically, researchers have used a genome-wide conjunctional analysis to identify 17 novel loci that overlap the conditions…

Adenosine Treatment Promotes Cartilage Homeostasis

Lara C. Pullen, PhD  |  June 26, 2017

A recent study in mice examined the role of adenosine A2A receptors in joint health. Researchers specifically found that as extracellular levels of adenosine fall, individuals may become at risk for osteoarthritis…

Promising Treatment for Eosinophilic Granulomatosis with Polyangiitis

Lara C. Pullen, PhD  |  June 20, 2017

A recent study showed that patients with eosinophilic granulomatosis with polyangiitis taking mepolizumab had longer disease remission than those on placebo. Some patients were able to discontinue prednisone during the study…

Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease

Lara C. Pullen, PhD  |  June 14, 2017

Complement can deposit in various tissues, and previous studies have associated complement deposition with an increased risk for all-cause mortality and stroke. Now, new research underscores the relationship between rheumatic disease, the complement system and cardiovascular disease. In particular, inflammatory rheumatic disease status appears to be uniquely associated with mononuclear cell infiltrates in the vascular…

Innate Immune Response Predicts Development of Non-Hodgkin’s Lymphoma in Sjögren’s Syndrome

Lara C. Pullen, PhD  |  June 12, 2017

The P2X7 receptor inflammasome axis may have a role in the pathogenesis of Sjögren’s syndrome and non-Hodgkin’s lymphoma. According to new research, patients with Sjögren’s syndrome who developed non-Hodgkin’s lymphoma had an increased expression of the P2X7R-inflammasome axis and the glandular expression of IL-18, suggesting a possible novel biomarker…

Anti-Drug Antibodies May Affect RA Treatment

Lara C. Pullen, PhD  |  June 5, 2017

A recent study examined the level of anti-drug antibodies (ADAs) in RA patients taking the TNF inhibitors adalimumab, infliximab and etanercept. Study patients without ADAs experienced better clinical outcomes, while patients with detectable ADAs had significantly lower serum trough drug concentrations…

  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 40
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences